underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .196854.1 possible withinthe specificchemicaldesignation: existence oftheseisomers,esters, ethers andsaltsis and ethers,unlessspecificallyexempted, wheneverthe isomers, esters,ethers,salts,and salts ofisomers,esters substances areincludedinSchedule I: Chapter 84,Section6,asamended)isamendedtoread: BE ITENACTEDBYTHELEGISLATUREOFSTATENEWMEXICO: OF SCHEDULEICONTROLLEDSUBSTANCES. SUBSTANCES ACTTOADDANDREMOVECERTAININTHELIST RELATING TOCONTROLLEDSUBSTANCES;AMENDINGTHE 51 ST LEGISLATURE "30-31-6. SCHEDULEI.--Thefollowingcontrolled SECTION 1. SENATE PUBLICAFFAIRSCOMMITTEESUBSTITUTEFOR A. anyofthefollowingopiates,including their SENATE JUDICIARYCOMMITTEESUBSTITUTEFOR Section30-31-6NMSA1978(beingLaws1972, - (1) acetylmethadol;

STATE

OF SENATE BILL127

NEW AN ACT

MEXICO

- SECONDSESSION ,

2014 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .196854.1 SJC/SPAC/SB 127 [(16) [(6) [(24) [(23) [(22) [(21) [(20) [(19) [(18) [(17) (17) difenoxin; [(15) [(14) [(13) [(12) [(11) [(10) [(9) [(8) [(7) (6) -methylfentanyl; (5) alphamethadol; (4) alphameprodine; (3) alphacetylmethadol; (2) allylprodine; ] (10) ] (9) ] (8) ] (7) ] (20) ] (19) ] (18) ] (16) ] (15) ] (14) ] (13) ] (12) ] (11) ] (26) ] (25) ] (24) ] (23) ] (22) ] (21) betameprodine; betacetylmethadol; benzethidine; betamethadol; furethidine; etoxeridine; ; ethylmethylthiambutene; dipipanone; dioxaphetylbutyrate; dimethylthiambutene; dimepheptanol; dimenoxadol; diethylthiambutene; diampromide; ; dextromoramide; clonitazene; betaprodine; - 2 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .196854.1 designation: salts ofisomersispossiblewithin the specificchemical exempted, whenevertheexistenceof these salts,isomersand salts, isomersandsaltsofisomers, unlessspecifically B. anyofthefollowingopiumderivatives, their (44) tilidine;and [(42) [(34) [(33) [(32) [(31) [(30) [(29) [(28) [(27) [(26) (1) acetorphine; [(41) [(40) [(39) [(38) [(37) [(36) [(34) [(25) ] (45) ] (43) ] (42) ] (41) ] (40) ] (39) ] (38) ] (37) ] (36) ] (35) ] (34) ] (33) ] (32) ] (31) ] (30) ] (29) ] (28) ] (27) norpipanone; normethadone; norlevorphanol; noracymethadol; morpheridine; levophenacylmorphan; levomoramide; ; hydroxypethidine; trimeperidine; racemoramide;[and properidine; proheptazine; piritramide; phenoperidine; phenomorphan; phenampromide; phenadoxone; - 3 ] SJC/SPAC/SB 127 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .196854.1 SJC/SPAC/SB 127 (26) acetyl-alpha-methylfentanyl; (25) 3-methylthiofentanyl; (24) beta-hydroxy-3-methylfentanyl; (23) drotebanol; (22) thebacon; (21) pholcodine;[and (20) normorphine; (19) nicomorphine; (18) nicocodeine; (17) myrophine; (16) -N-oxide; (15) morphinemethylsulfonate; (14) morphinemethylbromide; (13) methyldihydromorphine; (12) methyldesorphine; (11) hydromorphinol; (10) ; (9) etorphine; (8) dihydromorphine; (7) desomorphine; (6) ; (5) codeine-N-oxide; (4) codeinemethylbromide; (3) benzylmorphine; (2) acetyldihydrocodeine; - 4 ] underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 chemical designation: isomers andsaltsofispossiblewithinthespecific specifically exempted,whenevertheexistenceofthesesalts, substances, theirsalts,isomersandsaltsofisomers,unless that containsanyquantityofthefollowinghallucinogenic .196854.1 provided intheControlled SubstancesAct; or (STP) ; C. anymaterial,compound,mixtureorpreparation (5) (DET) (4) bufotenine; (3) 3,4,5-; (2) 5-methoxy-3,4-methylenedioxyamphetamine; (1) 3,4-methylenedioxyamphetamine; [(10) marijuana; (9) lysergicaciddiethylamide; (8) ; (7) 4-methyl-2,5-dimethoxy-(DOM) (30) thiofentanyl (29) para-fluorofentanyl;and (28) beta-hydroxfentanyl; (11) (6) dimethyltryptamine(DMT) [(13) [(12) (27) alpha-methylthiofentanyl; ] (10) ] (12) ] (11) ; N-ethyl-3-piperidyl benzilate; peyote,exceptasotherwise - 5 ; ; ; SJC/SPAC/SB 127 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .196854.1 propylthiophenethylamine (-T-7); or (TPCP); (pyrrolidine analogofphencyclidine); (ethylamine analogofphencyclidine); ); delta-9-tetra-hydrocannabinol (THC),anactiveingredientof SJC/SPAC/SB 127 (25) alpha-ethyltryptamine; (24) thiopheneanalogofphencyclidine(TCP) (23) 1-(1-phenylcyclohexyl)pyrrolidine(PCPy), (22) N-ethyl-1-phenylcyclohexylamine(PCE), (21) 4-methoxyamphetamine(PMA); (20) 4-bromo-2,5-dimethoxy-amphetamine(DOB); (19) 2,5-dimethoxyamphetamine(DMA); (30) 5-methoxy-N,N- (29) alpha-methyltryptamine (AMT); (28) 2,5dimethoxy-4-(n)- (27) ibogaine; (26) 2,5-dimethoxy-4-ethylamphet-amine; (18) (syntheticanalogof [(19) syntheticcannabinoids,including [(18) [(17) [(16) [(15) [(14) ] (17) ] (16) ] (15) ] (14) ] (13) hashish; ; psilocyn; ; N-methyl-3-piperidylbenzilate; - 6 ] underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 including anymaterial,compound,mixtureorpreparationthat specifically exemptedorunlesslistedinanotherschedule, .196854.1 iodobenzoyl)indole); pentylindol-3-yl)methanone; chlorophenylacetyl)indole); 10,10a-tetrahydro -6,6,9-trimethyl-6Hdibenzo[b,d]pyran; naphthoyl)indole); methoxynaphthoyl)]indole); hydroxypropyl) cyclohexyl)-5-(2-methyloctan-2-yl)phenol); decahydronaphthalen-2-ol); hydroxy-4-(2-methyloctan-2-yl)phenyl] 1,2,3,4,4a,5,6,7,8,8a- analogs orhomologswithbindingactivity,including: demonstrate bindingactivitytothecannabinoidreceptoror contains anyquantityofsyntheticcannabinoidsthat (5-MeO-DIPT); (31) syntheticcannabinoids,unless (f) JWH203(1-pentyl-3-(2- (e) JWH-1333-(1,1-dimethylbutyl)-6a,7, (d) JWH-122(1-pentyl-3-(4-methyl-1- (c) JWH-081(1-pentyl-3-[1-(4- (b) CP55,940((5-hydroxy-2-(3- (a) CP55,244((hydroxymethyl)-4-[2- (i) AM-1221(1-(N-methylpiperdin)-2-yl) (h) AM-694(1-(5-fluoropentyl)-3-(2- (g) JWH2104-ethylnaphthalen-1-yl-(1- - 7 SJC/SPAC/SB 127 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 naphthoyl)indole); .196854.1 extent, including, butnotlimitedto,JWH-015,JWH-018, and whetherornot substitutedinthenaphthylringto any or notfurthersubstitutedintheindole ringtoanyextent, piperidinyl) methylor2-(4-morpholinyl) ethylgroup,whether alkenyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2- at thenitrogenatomofindolering byanalkyl,haloalkyl, containing a3-(1-naphthoyl)indole structure withsubstitution chemical designation:1)naphthoylindoles,oranycompound isomers andsaltsofispossiblewithinthespecific specifically excepted,whenevertheexistenceofthesesalts, , theirsalts,isomersandsaltsofisomers,unless naphthalenylmethanone; 3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin6-yl)-1- methanone; methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl] (2-methoxyphenylacetyl)indole); methoxy)-benzoyl]indole); methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole; SJC/SPAC/SB 127 (o) anyofthefollowingsynthetic (n) WIN-55,212-2(2,3-dihydro-5-methyl- (m) WIN-49,098()(4- (l) RCS-8orSR-18(1-cyclohexylethyl-3- (k) RCS-4orSR-19(1-pentyl-3-[(4- (j) AM-2201(1-(5-fluoropentyl)-3-(1- - 8 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 substitution atthenitrogenatomofindoleringbyan containing a1hindol-3-yl-(1-naphthyl)methanestructurewith and AM-2201;2)naphthylmethylindoles,oranycompound .196854.1 but notlimitedto, JWH-176;5)phenylacetylindoles,or any not substitutedin thenaphthylringtoanyextent,including, substituted intheindeneringtoany extent,andwhetheror methyl or2-(4-morpholinyl)ethylgroup, whetherornotfurther cycloalkylmethyl, cycloalkylethyl,1-(N-methyl-2-piperidinyl) 3-position oftheindeneringbyan alkyl, haloalkyl,alkenyl, naphthylideneindene structurewithsubstitution atthe naphthylmethylindenes, oranycompoundcontaininga extent, including,butnotlimitedto,JWH-307;4) and whetherornotsubstitutedinthenaphthylringtoany or notfurthersubstitutedinthepyrroleringtoanyextent, piperidinyl) methylor2-(4-morpholinyl)ethylgroup,whether alkenyl, cycloalkylmethyl,cycloalkylethyl,1-(N-methyl-2- nitrogen atomofthepyrroleringbyanalkyl,haloalkyl, 3-(1-naphthoyl) pyrrolestructurewithsubstitutionatthe and JWH-199;3)naphthoylpyrroles,oranycompoundcontaininga to anyextent,including,butnotlimitedto,JWH-175,JWH-184 any extent,andwhetherornotsubstitutedinthenaphthylring group, whetherornotfurthersubstitutedintheindoleringto 1-(N-methyl-2-piperidinyl) methylor2-(4-morpholinyl)ethyl alkyl, haloalkyl,alkenyl,cycloalkylmethyl,cycloalkylethyl, JWH-019, JWH-073,JWH-081,JWH-122,JWH-200,JWH-210,JWH-398 - 9 SJC/SPAC/SB 127 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 1-(N-methyl-2-piperidinyl) methylor2-(4-morpholinyl)ethyl alkyl, haloalkyl,alkenyl,cycloalkylmethyl,cycloalkylethyl, substitution atthenitrogenatomofindoleringbyan .196854.1 AM-1241; but notlimitedto,AM-694,pravadoline (WIN48,098),RCS-4and not substitutedinthephenylringto anyextent,including, substituted intheindoleringtoany extent,andwhetheror methyl or2-(4-morpholinyl)ethylgroup, whetherornotfurther cycloalkylmethyl, cycloalkylethyl,1-(N-methyl-2-piperidinyl) atom oftheindoleringbyanalkyl,haloalkyl,alkenyl, OTS-3833.4 indolestructurewithsubstitutionatthenitrogen benzoylindoles, oranycompoundcontaininga3-(benzoyl)[5] 47,497 C8homologue),CPand55,490;7) extent, including,butnotlimitedto,(CP group, whetherornotsubstitutedinthecyclohexylringtoany 1-(N-methyl-2-piperidinyl) methylor2-(4-morpholinyl)ethyl alkyl, haloalkyl,alkenyl,cycloalkylmethyl,cycloalkylethyl, substitution atthe5-positionofphenolicringbyan containing a2-(3-hydroxycyclohexyl)phenolstructurewith JWH-251 andRCS-8;6)cyclohexylphenols,oranycompound to anyextent,including,butnotlimitedto,JWH-203,JWH-250, any extent,andwhetherornotsubstitutedinthephenylring group, whetherornotfurthersubstitutedintheindoleringto compound containinga3-phenylacetylindolestructurewith SJC/SPAC/SB 127 (p) UR-1441-(pentyl-1H-indol-3-yl)(2,2, - 10 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .196854.1 naphthoyl) indole; -3-(1-naphthoyl)indole; -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; -9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) tetrahydrobenzo[c]chromen-1-ol; -6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; -3-hydroxycyclohexyl]-phenol (CP-47,497);and5-(1, 497 andhomologues:5-(1,1-dimethylheptyl)-2-[(1R,3S) methoxyphenylacetyl) indole; indole; 3-yl(2,2,3,3-tetramethylcyclopropyl)methanone; indazole-3-carboxamide; 3,3-tetramethylcyclopropyl)methanone; [(a) (r) AKB48N-(1-adamantyl)-1-pentyl-1H- (q) XLR111-(5-fluoro-pentyl)-1H-indol- [(d) [(c) [(b) [(i) [(h) [(g) [(f) [(e) ] (u) ] (t) ] (s) ] (aa) ] (z) ] (y) ] (x) ] (w) ] (v) - 11 1-hexyl-3-(1-naphthoyl)indole; 1-butyl-3-(1-napthoyl)indole; 1-[2-4-(morpholinyl)ethyl] ,(6aS,10aS) (6aR,10aR)-9-(hydroxymethyl) cannabicyclohexanol,CP47, 1-pentyl-3-(2- 1-pentyl-3-(1-naphthoyl) 1-pentyl-3-(4-chloro SJC/SPAC/SB 127 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 hydroxy cyclohexyl)-phenol; 3-yl)-1-naphthalenyl-methanone; and .196854.1 (); (ethcathinone); -dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate); 9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10 liability, including: of thesubstancetoproducepsychicorphysiologicaldependence the publichealthbyabuseofsubstanceandpotential have thepharmacologicaleffectofsubstance,riskto SJC/SPAC/SB 127 (25) (42) 3',4'-methylenedioxyethcathinone (41) 2-ethylamino-1-phenyl-propan-1-one (40) 4-ethyl-methcathinone(4-EMC); (39) 4-methyl-ethylcathinone(4-MEC); [(20) [(24) [(23) [(22) [(21) (38) substancesdeterminedbytheboardto ] (37) ] (36) ] (35) ] (34) ] (33) ] (32) (b) salvinorinA(methyl(2S,4aR,6aR,7R, (a) salviadivinorum;and [(k) [(j) ] (cc) ] (bb) 4-fluoromethcathinone; 3-fluoromethcathinone;[and 4-methoxymethcathinone; 4-methylmethcathinone; 3,4-methylenedioxypyrovalerone; 3,4-methylenedioxymethcathinone; - 12 5-(1,1-dimethylheptyl)-2-(3- (2-methyl-1-propyl-1H-indol- underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 benzodioxyolybutanamine (bk-MBDB,); .196854.1 (eutylone); and (buphedrone); PVP); (MPBP); pyrrolidinobutiophenone (MDPBP); pyrrolidinopropiophenone (MDPPP); (MPPP); (MOPPP); PBP); PPP); (53) alpha-pyrrolidinovalerophenone (alpha- (52) 4'-methyl-alpha-pyrrolidinobutiophenone (51) 3',4'-methylenedioxy-alpha- (50) 3',4'-methylenedioxy-alpha- (49) 4'-methyl-alpha-pyrrolidinopropiophenone (48) 4'-methoxy-alpha-pyrrolidinopropiophenone (47) alpha-pyrrolidinobutiophenone(alpha- (46) alpha-pyrrolidinopropiophenone(alpha- (45) N,N-dimethylcathinone(metamfepramone); (44) naphthylpyrovalerone(NRG-1,naphyrone); (56) beta-keto-ethylbenzodioxolylbutanamine (55) alpha-methylamino-butyrophenone (54) 5,6-methylenedioxy-2-aminoindane (MDAI); (43) beta-keto-N-methyl-3,4- - 13 SJC/SPAC/SB 127 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 or unlesslistedinanotherschedule,includinganymaterial, (pentylone); .196854.1 designation: salts ofisomersispossiblewithinthespecificchemical of isomers,whenevertheexistencesuchsalts,isomersand central nervoussystem,includingitssalts,isomersandsalts the followingsubstanceshavingadepressanteffecton compound, mixtureorpreparationthatcontainsanyquantityof SJC/SPAC/SB 127 D. anyofthefollowing,unlessspecificallyexempt (3) benzodiazepines,including: (2) methaqualone; (1) mecloqualone; (57) beta-keto-ethylbenzodioxolylpentanamine (f) fludiazepam; (e) ethylloflazepate; (d) delorazepam; (c) cloxazolam; (b) camazepam; (a) bromazepam; (l) medazepam; (k) lormetazepam; (j) loprazolam; (i) ketazolam; (h) haloxazolam; (g) flunitrazepam; - 14 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .196854.1 ); salts ofisomers: on thecentralnervoussystem,includingitssalts,isomersand quantity ofthefollowingsubstanceshavingastimulanteffect material, compound,mixtureorpreparationthatcontainsany exempted orunlesslistedinanotherschedule,includingany that ismetabolicallyconvertedtoGHB; compound thatismetabolicallyconvertedtoGHB;and compound thatismetabolicallyconvertedtoGHB; E. anyofthefollowing,unlessspecifically F. anymaterial, compound, mixtureorpreparation (1) fenethylline; (6) 1-4butanediolandanychemicalcompound (5) gammabutyrolactoneandanychemical (4) gammahydroxybutyricacidandanychemical (5) N-benzylpiperazine(BZP,1- (4) N,N-dimethylamphetamine;and (3) cis-4-methylaminorex; (2) N-ethylamphetamine; (r) tetrazepam; (q) pinazepam;and (p) oxazolam; (o) nordiazepam; (n) nitrazepam; (m) nimetazepam; - 15 SJC/SPAC/SB 127 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 and geometricisomers,saltsofisomers; ethyl)-4-piperidyl)-N-phenylpropanamide, includingitsoptical salts ofisomers; piperidine (PEPAP),includingitsopticalisomers,saltsand isomers; (MPPP), includingitsopticalisomers,salts,andsaltsof and saltsofisomers; including itsoptical,positionalandgeometricisomers,salts .196854.1 tetrahydrocannabinols orchemicalderivativesof that containsanyquantityofthefollowingsubstances: SJC/SPAC/SB 127 Control Actof1970andallotherrequirements oflaw; comply withthefederalComprehensive DrugAbusePreventionand distributes peyotetotheorganization oritsmembersshall registration. Anypersonwhomanufactures peyoteforor members oftheorganizationsousing peyoteareexemptfrom religious ceremoniesbyabonafideorganization,and substance doesnotapplytotheuseofpeyoteinbonafide [D. [E. ] H. ] G. (6) methcathinone; (5) cathinone;and (4) 1-(-2-phenylethyl)-4-phenyl-4-acetoxy (3) 1-methyl-4-phenyl-4-proprionoxypiperidine (2) 3,4-methylenedioxymethamphetamine(MDMA), (1) 3-methylfentanyl(N-3-methyl-1-(2-phenyl- theenumeration of [marijuana theenumerationofpeyoteasacontrolled - 16 ] underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 provisions oftheLynnandErinCompassionateUseAct; Research Actorbyqualifiedpatientspursuanttothe patients pursuanttotheControlledSubstancesTherapeutic chemical derivativesoftetrahydrocannabinolbycertified not applytotheuseof[marijuana asScheduleIcontrolledsubstancesdoes 1978." by ruleadoptedtheboardpursuanttoSection30-31-3NMSA .196854.1 [F. ] I. controlledsubstancesaddedtoScheduleI - 17 ] tetrahydrocannabinolsor SJC/SPAC/SB 127